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Abstract
Background: Identification of biomarkers associated with the prognosis of different cancer subtypes is critical to
achieve better therapeutic assistance. In colorectal cancer (CRC) the discovery of stable and consistent survival
markers remains a challenge due to the high heterogeneity of this class of tumors. In this work, we identified a
new set of gene markers for CRC associated to prognosis and risk using a large unified cohort of patients with
transcriptomic profiles and survival information.
Results: We built an integrated dataset with 1273 human colorectal samples, which provides a homogeneous
robust framework to analyse genome-wide expression and survival data. Using this dataset we identified two sets
of genes that are candidate prognostic markers for CRC in stages III and IV, showing either up-regulation correlated
with poor prognosis or up-regulation correlated with good prognosis. The top 10 up-regulated genes found as
survival markers of poor prognosis (i.e. low survival) were: DCBLD2, PTPN14, LAMP5, TM4SF1, NPR3, LEMD1, LCA5,
CSGALNACT2, SLC2A3 and GADD45B. The stability and robustness of the gene survival markers was assessed by
cross-validation, and the best-ranked genes were also validated with two external independent cohorts: one of
microarrays with 482 samples; another of RNA-seq with 269 samples. Up-regulation of the top genes was also proved
in a comparison with normal colorectal tissue samples. Finally, the set of top 100 genes that showed overexpression
correlated with low survival was used to build a CRC risk predictor applying a multivariate Cox proportional hazards
regression analysis. This risk predictor yielded an optimal separation of the individual patients of the cohort according
to their survival, with a p-value of 8.25e-14 and Hazard Ratio 2.14 (95% CI: 1.75–2.61).
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Conclusions: The results presented in this work provide a solid rationale for the prognostic utility of a new set of
genes in CRC, demonstrating their potential to predict colorectal tumor progression and evolution towards poor
survival stages. Our study does not provide a fixed gene signature for prognosis and risk prediction, but instead
proposes a robust set of genes ranked according to their predictive power that can be selected for additional tests
with other CRC clinical cohorts.
Keywords: Cancer, Colorectal cancer, Colon, Survival, Kaplan-Meier analysis, Gene marker, Bioinformatics,
Transcriptomics, Gene Expression
Background
Colorectal cancer (CRC) is one of the most frequent
tumors that causes great morbidity worldwide. It is the
third most common cancer in men, the second most
common cancer in women and the third leading cause
of global cancer mortality (https://www.wcrf.org/). CRC
is a heterogeneous disease since from one patient to an-
other it differs in clinical presentation, molecular charac-
teristics, and prognosis [1]. The heterogeneity of CRC
increases the complexity of this tumoral pathology,
making subtyping and stratification a difficult task for
therapeutic decisions. In this way, personalized medicine
for CRC is becoming increasingly needed, especially for
targeted therapies where large variations between indi-
vidual’s treatment responses exist [1, 2]. In this context,
the need to find robust gene markers associated with
specific subtypes of CRC led us to this study. Further-
more, the specific purpose of our work was to find con-
sistent biomolecular targets that, together to facilitate
samples stratification, could be related to the prognosis
of the disease using survival data.
The genomic and transcriptomic profiling of human
cancer samples has been demonstrated over the last de-
cade as an excellent way to obtain a better molecular
characterization of many tumor types and subtypes.
While gene expression-based CRC classifications has
been heavily approached [2], little consensus in CRC
standalone gene bio-marking has been achieved. In fact,
several studies have identified a broad variety of gene
sets as gene expression profiles for classification and
categorization of this malignant disorder [3, 4]. More-
over, several transcriptomic-based tests oriented towards
prognosis have also been investigated. Some examples of
these are: ColoLipidGene [5], ColoGuidePro [6] or
ColoPrint [7]; that include gene signatures associated
with CRC survival in some specific biological contexts.
Despite these efforts, at present there is not a clear com-
pendium of gene markers for CRC survival and it is
quite difficult to find consistency in the literature.
In the clinic, patients are classified into four CRC
stages based in the anatomo-pathologycal characteristics
of their tumors. It is common to use the TNM Staging
System (where T stands for tumor, N for lymph node,
and M for metastasis). The disease “staging” also allows
grouping the patients in 4 progressive cancer stages, in-
dicated by roman numerals: I, II, III, and IV [8]. In this
way, stages I and II correspond to cases which had not
shown cancer cells beyond the tumor or blood. By
contrast, stages III and IV correspond to individuals in
where the cancer had diseminate to the lymph system or
other organs in the body. This four stage categorization
represents significantly distinctive patients groups for
final outcome or disease relapse, but the stages do not
predict the risk of each individual patient because they
are not directly associated to survival [9].
Based on the described need and potential benefits to
find survival marker genes correlated with high risk and
poor prognosis in CRC; we investigated global gene ex-
pression profiles of colorectal tumors and its alteration
throughout stages, to identify genes that could be
levered as biomarkers of survival and prognosis for CRC
in late stages (i.e., III and IV). To undertake this work
we performed a deep analysis on a large cohort of
human samples derived from a robust integration of se-
veral datasets that had transcriptomic and clinical
survival data. The integration provided a homogeneous
and well-standardized meta-dataset that includes 1273
human colorectal samples. The identification of candi-
date markers was performed using an initial contrast
between the gene expression of the subset of patients
with CRC allocated by their clinical features to stages I
and II versus the patients with tumors corresponding to
stages III and IV. Finally, after internal and external
cross-validation, the genes selected as best survival markers
were used to construct a risk predictor to allow stratifica-
tion of the patients with respect to their relative risk.
Results
A large dataset of CRC samples including global
expression and survival data
We first built a large cohort of CRC samples collected
from individuals that had clinical record with survival
data times, as well as genome-wide expression profiles
of their colorectal primary tumors at diagnosis (i.e.
before any drug treatment). Our aim was to achieve a
meta-dataset with at least 1 thousand samples and to
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demonstrate a good integration of the global transcrip-
tomic profiles of different samples sets avoiding the ty-
pical batch-effects that can alterate any unified analysis.
Table 1 presents the datasets of CRC samples that
were collected to produce the integrated dataset
analysed in this work. All the CRC samples included in
this meta-dataset were tested for global gene expression
profiling using the platform of high-density microarrays
from Affymetrix: Human Genome U133 Plus 2.0. Using
this platform, the probesets of the arrays were mapped
to single genes (as indicated in Risueño et al.) [10] and,
in this way, each microarray measured the expression
signal of 20,079 human genes (using the mapping provided
by the Chip Description File, CDF v.21 from: http://brainar-
ray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/).
As a whole, Table 1 includes 7 series that were ob-
tained from the Gene Expression Omnibus repository
(GEO, https://www.ncbi.nlm.nih.gov/geo/). These data-
sets included a total amount of 1352 CRC samples, but
after collecting the clinical survival data and carrying
out the integration and normalization protocols we fi-
nished with 1273 samples, since we filtered 79 samples
that did not have survival data or did not show
comparable data distributions after normalization. The
phenotypic and clinical information about the final
collection of 1273 samples, i.e., the available data about
age, gender, survival time, location of the tumor, degree
and TNM staging, presence of mutation in some cancer
genes (TP53, KRAS, BRAF), etc.; is included in
Additional file 1: Table S1. When information was not
available for a given sample the table includes not
assigned values (NA).
Evaluation of normalization procedures to integrate
independent batches
We performed the integration and combined normalization
of the CRC expression datasets using 5 different proce-
dures. The procedures applied different normalization algo-
rithms to provide a homogeneous signal matrix, avoiding
bias due to batch effect on the global expression profile of
the CRC samples. The procedures applied were: (i) Robust
Multi-array Average (RMA) algorithm [11]; (ii) RMA plus
Combatting Batch effects (ComBat) algorithm [12]; (iii)
Frozen Robust Multi-array Average (fRMA) algorithm [13];
(iv) fRMA plus Combat; (v) fRMA plus scaling of the data
using mean-centered expression values.
Table 1 Summary information about the series of colorectal cancer (CRC) samples that were collected to produce the integrated
data set analyzed in this work
GEO
dataset
Sample Source Sample Description Total
samples
in dataset






GSE14333 Royal Melbourne Hospital, Western Hospital
and Peter MacCallum Cancer Center,




290 19996206 Jorissen RN
et al. (2009)
64 226
GSE17536 Moffitt Cancer Center, USA colorectal cancer
patients
177 19914252 Smith JJ et al.
(2010)
0 177
GSE31595 Roskilde Hospital, DENMARK patients with stage
II and III colorectal
cancer
37 – Thorsteinsson M
et al. (2011)
0 37





90 22496204 Kemper K et al.
(2012)
0 90
GSE38832 Vandervilt University Medical Center, USA tumor samples
collected from
colorectal patients
122 25320007 Tripathi MK
et al. (2014)
0 122
GSE39084 Toulouse Hospital, FRANCE sporadic early onset
primary colorectal
carcinomas
70 25083765 Kirzin S et al.
(2014)
1 69
GSE39582 Institut G. Roussy (Villejuif), Hosp. Saint
Antoine (Paris), Hosp. G.Pompidou (Paris),
Hosp. Hautepierre (Strasbourg), Hosp.
Purpan (Toulouse), Institut P. Calmettes










All the CRC samples were tested for global gene expression profiling using high-density microarrays Human Genome U133 Plus 2.0 from Affymetrix (that measure
the signal of 20,141 human genes). The total collection included 1352 samples, but only 1273 were finally used. A group of 79 samples were discarded because
they did not have survival data or they presented anomalous data distributions with respect to the other samples of the same series
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To evaluate and compare the results provided by each
one of these 5 procedures we carried out several ana-
lyses. Figure 1 presents the heatmaps derived from an
unsupervised clustering of the samples using in each
case the expression data matrix derived from each one
of the 5 procedures applied. Due to the fact that each
series has a different number of samples (one with more
than 500 and several other with less than 100), we did a
random selection of an even number of samples for each
dataset to be included in the cluster analysis: 30 samples
from each one. In this way, each heatmap is composed
of 210 samples (30 × 7): 30 samples from each one of the
7 datasets (identified by the ID number, GSE, from
GEO). In Fig. 1 the samples of each batch are identi-
fied by a color that is indicated in the horizontal bar
below the dendrograms. Each heatmap represents a
different preprocessing and normalization method
performed to merge the datasets in one meta-dataset.
The results shown in these clustering analyses indi-
cate that in the case of methods that gave the heat-
maps A, C and E, several samples of the same color
are grouped together showing that they have a com-
mon correlation profile within the global expression
signature. By contrast, in the case of methods that
gave the heatmaps B and D, there is a clearer shuf-
fling of all the colors, which reflects a homogenous
mix of the overall expression signal coming from
different datasets.
The clustering analysis presented in the symmetric
heatmaps of Fig. 1 was done using, for each sample, a
vector including the expression signals along all genes
and calculating with these vectors the pair-wise Pearson
correlations between samples and the pair-wise distance
matrix derived from such correlations. This approach
can reveal major effects associated to the global expres-
sion signal of the samples, but it is not very sensitive to
detect minor changes in a small number of genes. For
this reason we applied a second approach to compare
the results provided by the 5 normalization procedures
in order to select the one that produces the best unifica-
tion of the 7 CRC datasets, preserving a good signal to
noise ratio in the expression distributions. Algorithms of
dimensionality reduction, such as PCA (Principal
Component Analysis), allow exploring large datasets in
an accurate way to identify factors that are relevant for
the variance of studied variables (in our case the expres-
sion of the genes in the unified meta-dataset of 1273
samples). Figure 2 presents the plots derived from the
PCA done over the 5 expression matrices (i.e. the signal
of 20,079 genes in 1273 samples) obtained with 5 differ-
ent normalization approaches. These results show very
clearly that the RMA method (Fig. 2a) is not good to
Fig. 1 Symmetric heatmaps representing the similarity between the overall gene expression signal of the samples compared with each other.
Each heatmap is composed of 210 samples (30 × 7, 30 samples random selected from each batch, i.e. from each one of the 7 GSE datasets). The
samples of each batch are identified by a color in the top bar below the top dendrograms (following the colors legend). Each heatmap
represents a different preprocessing and normalization method performed to merge the datasets in one batch. The methods applied were: a
RMA; b RMA plus ComBat; c fRMA; d fRMA plus ComBat; e fRMA plus scaling of the data using mean-centered expression values
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provide a proper normalization of different batches,
since the samples keep a very strong signal associated to
each batch. The fRMA method (Fig. 2c) neither is good,
since some samples (specially the ones from the largest
batch GSE39582) still keep a strong signal associated to
their batch. By contrast, the analysis of the data provided
by the other 3 procedures (RMA plus Combat, fRMA
plus Combat and fRMA plus mean-centered scaling, Fig.
2b, d and e, respectively) showed an adequate mix of all
the samples from different batches. Within these 3
procedures, the normalization is very similar keeping a
good signal to noise ratio along the genes and a small
signal reduction. We finally select option B, RMA plus
Combat, because the heatmap in Fig. 1b showed the best
mix between series and a better similarity between the
samples (compared to options D or E).
As a final testing to identify the best integration and
normalization procedure of the 7 CRC expression data-
sets, we carried out a linear regression analyses on the
global expression matrix considering as predictors 7 in-
dependent dummy variables or factors. These variables
correspond to the series from which each sample comes
from. In this way, if these factors have a significant influ-
ence in the expression signal distributions, the linear re-
gression analysis will show a significant p-value and
correlation. The results of this analysis are presented in
Table 2, that reveals again that only the data matrices
produced by the methods B and D (RMA plus Combat
and fRMA plus Combat, respectively) do not show a
significant effect attributed to belonging to one of the
series. Finally, we choose B versus D as the final proce-
dure applied because, despite being very similar, the ap-
plication of RMA plus Combat provoked less dramatic
changes with respect to the raw signal expression.
Identification of genes associated to advanced CRC that
mark survival differences
Once we produced a large and well-integrated meta-
dataset of CRC samples, having global expression pro-
files and clinical survival data for all cases, we proceed
to the identification of the subset of genes that suffer
significant changes with colorectal tumor progression.
To do this, we explored the overall expression matrix to
detect the genes that showed a significant expression
change when comparing CRC tumors in early stages
(stages I and II) versus CRC tumors in late or advanced
stages (stages III and IV). This comparison was done ap-
plying LIMMA, differential expression algorithm, and
retrieving all genes that gave a significant p-value (ad-
justed p < 0.05) in either direction (i.e., genes
up-regulated with the progression of the disease, in late
versus early CRC stages; or genes down-regulated with
the progression of the disease). Such differential expres-
sion analysis gave a subset of 2707 human genes: 2524
corresponding to protein-coding genes and the rest to
non-coding genes (in this work we focused only in the
protein-coding genes).
Fig. 2 Plots presenting the distribution of the 1273 samples from 7 datasets (GSEs) obtained by Principal Component Analysis (PCA) of the global
gene expression profile of each sample; that converts the signal of each sample using an orthogonal transformation in linearly uncorrelated
variables called principal components or dimensions. Each plot presents the values of the two main dimensions (dim 1 versus dim 2) and
corresponds to the PCA results obtained using the expression data calculated with different preprocessing and normalization methods. The
methods applied were: a RMA; b RMA plus ComBat; c fRMA; d fRMA plus ComBat; e fRMA plus scaling of the data using mean-centered
expression values. The samples of each batch are identified by color dots following the colors legend
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Table 2 Results of the linear regression analyses on the global expression matrix calculated for the 1273 samples from 7 datasets
(GSEs) combined using 5 different preprocessing and normalization methods
FACTORS considered Estimated coefficients std. error t value p.value Factor effect
(A) RMA
Intercept 6.925 0.014 512.610 <2e-16 –
(GSE14333+) GSE17536 0.387 0.019 20.230 <2e-16 yes
GSE31595 −1.212 0.019 −63.440 <2e-16 yes
GSE33113 −0.577 0.019 −30.210 <2e-16 yes
GSE38832 −0.355 0.019 −18.570 <2e-16 yes
GSE39084 −0.978 0.019 −51.180 <2e-16 yes
GSE39582 −1.375 0.019 −71.970 <2e-16 yes
(B) RMA plus Combat
Intercept 6.219 0.013 473.582 <2e-16 –
(GSE14333+) GSE17536 0.000 0.019 0.001 0.999 no
GSE31595 0.002 0.019 0.122 0.903 no
GSE33113 0.001 0.019 0.051 0.959 no
GSE38832 −0.001 0.019 −0.033 0.973 no
GSE39084 0.002 0.019 0.092 0.927 no
GSE39582 0.001 0.019 0.029 0.977 no
(C) fRMA
Intercept 6.535 0.015 450.434 <2e-16 –
(GSE14333+) GSE17536 −0.011 0.021 −0.553 0.580 no so much
GSE31595 0.089 0.021 4.329 0.000 yes
GSE33113 0.071 0.021 3.455 0.001 yes
GSE38832 0.054 0.021 2.641 0.008 yes
GSE39084 0.096 0.021 4.695 0.000 yes
GSE39582 0.089 0.021 4.336 0.000 yes
(D) fRMA plus Combat
Intercept 6.590 0.014 457.338 <2e-16 –
(GSE14333+) GSE17536 0.000 0.020 0.001 1.000 no
GSE31595 0.002 0.020 0.093 0.926 no
GSE33113 0.001 0.020 0.072 0.942 no
GSE38832 0.000 0.020 0.019 0.985 no
GSE39084 0.002 0.020 0.089 0.929 no
GSE39582 0.000 0.020 0.007 0.994 no
(E) fRMA plus mean centered
Intercept 0.000 0.000 −1.638 0.101 –
(GSE14333+) GSE17536 0.000 0.000 1.264 0.206 yes
GSE31595 0.000 0.000 0.288 0.773 no so much
GSE33113 0.000 0.000 1.605 0.108 yes
GSE38832 0.000 0.000 1.449 0.147 yes
GSE39084 0.000 0.000 −0.076 0.940 no
GSE39582 0.000 0.000 1.395 0.163 yes
The methods applied were: (A) RMA; (B) RMA plus ComBat; (C) fRMA; (D) fRMA plus ComBat; (E) fRMA plus scaling of the data using mean-centered expression
values. The linear regression is done to evaluate the “batch effect” (i.e. considering that the tested factors are the fact of “belonging” to a given dataset). Thus,
when the p-value of the factors are significant (< 0.05), the “batch effect” remains on the overall expression signal. A marginal low significance was considered
when p-values were < 0.20 in the case E
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Once we had the subset of genes that can be associ-
ated to advanced or progression of CRC, we perform a
second analysis on these gene candidates to find out
which ones can be correlated with the survival of the
corresponding patient samples based on their expression
signals. To do this, we carried out Kaplan-Meier (KM)
analysis of the survival times of the set of 1273 colorec-
tal cancer samples for each one of the 2524 genes found
in the previous exploration. In this analysis, the genes
were ranked considering the non-parametric log-rank
test that evaluates the separation between the two KM
curves for two prognostic groups: one with good survival
and another with poor survival. To do this, our
algorithm performs for each gene multiple splits of the
sample cohort in two groups, and looks for the splitting
that provides the best separation between groups (i.e.
the best p-value). Then, a stringent cut-off value
(adjusted p < 0.0003) was used to select the genes that
are considered significant. This allowed the identification
of 429 significant genes in which the overexpression cor-
related with low survival, plus 336 significant genes
where the repression correlated with low survival. These
analyses were done in a univariate mode, considering
each gene as an independent factor.
Figure 3 shows the Kaplan-Meier plots corresponding
to the survival profiles of the two populations of
individuals that were segregated according to the ex-
pression values of the gene tested. The 4 plots corres-
pond to the top genes: DCBLD2 and PTPN14 with
overexpression correlated to low survival; and EPHB2
and DUS1L with repression correlated to low survival.
The separation of the two populations in both cases
is very significant, with KM p-values < 1.0e-10 and
Hazard Ratios (HR) around 2.0 for overexpression
cases and around 0.45 for repression cases. These
parameters were calculated using all the 1273
samples; however it was necessary to do an internal
cross-validation of these results to assess how stable
and reliable was the signal for each one of the
selected genes.
We carried out a cross-validation of the top-200 genes
selected in any of the two conditions (i.e. selected as sur-
vival markers when they were up-regulated for the cases
of poor survival or when they were up-regulated for the
cases of better survival). This internal cross-validation
was done using for each gene a resampling strategy that
randomly selected 80% of the sample 100 times (i.e.
doing 100 iterations). The results corresponding to the
top 100 genes are included in Additional file 2: Table S2,
for the case of up-regulation for poor survival, and the
other top 100 genes in Additional file 3: Table S3, for
the case up-regulation for better survival.
Fig. 3 Kaplan-Meier plots of the survival analysis of the set of 1273 samples from colorectal cancer (CRC) patients. The patients are separated in
two groups (high in red and low in green) according to the expression profiles of 4 genes: a DCBLD2, b PTPN14, c EPHB2, d DUS1L. These genes
provided the best split between patients of high and low risk based in their expression levels. In the case of genes DCBLD2 and PTPN14 (labelled
in red) the over-expression is correlated with poor survival; and in the case of genes EPHB2 and DUS1L (labelled in green) the over-expression is
correlated with good survival. In all cases the adjusted p.values of the analyses are very significant (as indicated inside each plot), indicating that
the two populations represented by the two curves have a very clear difference in their overall survival
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A short view of these data is shown in Table 3 that
presents the 50 genes selected as best survival markers of
CRC: the first part of the table corresponds to the top 25
genes, where up-regulation corresponds to shorter sur-
vival and higher risk (HR > 1); the second part of the table
corresponds to the top 25 genes, where up-regulation cor-
responds to longer survival and lower risk (HR < 1). The
genes were ranked by their KM p-values and the HR
values calculated for the whole dataset (i.e. for all the 1273
samples, all-dt). As indicated, the stability and robustness
of the gene survival markers was assessed via a resampling
strategy with random selection of 80% of the dataset 100
times. For the final ranking of the genes included in these
tables we also considered that they had to give a signifi-
cant adjusted p-value in more than 80 out of 100 boot-
strap iterations (i.e. N-sinf-in-100i > 80).
External validation of prognostic markers with a CRC
cohort studied using RNA-seq
The analyses done so far provided a ranked collection of
genes found as robust markers of survival in CRC. The
consistency of the results obtained with the internal
cross-validation gives strong support to the top genes
found (presented in Table 3), but we had to consider the
value of using other external independent CRC cohorts
to corroborate these findings. As far as we could investi-
gate we did not find other large CRC datasets (i.e., sets
with more than one thousand samples) that included
global gene expression data plus survival as part of the
clinical characterization of samples. Despite this limita-
tion, we look for independent datasets and found in The
Cancer Genome Atlas (TCGA, http://tcga-data.nci.nih.
gov/docs/publications/coadread_2012/) a
well-characterized cohort of 276 colorectal carcinomas
that had been studied with several genome-scale tech-
nologies (including RNA-seq gene expression profiling)
and that had survival data for 269 samples [14]. We used
these data to validate the top genes found as best
survival markers in our previous analysis. The results in-
dicated a good performance in more than two thirds of
the genes tested. In Additional file 4: Table S4 we
present the KM p-values and HR of the genes that were
validated from the top 10 previously found: 7 genes of
the top 10 for the case of up-regulation associated with
poor survival (PTPN14, LAMP5, TM4SF1, LCA5,
CSGALNACT2, SLC2A3 and GADD45B) and 6 genes of
the top 10 previously found for the case of up-regulation
associated with good survival (EPHB2, DUS1L, NUAK2,
FANCC, MYB and CHDH).
External validation of prognostic markers using
multivariate survival analysis
Up to now the search to find gene survival markers as-
sociated to the prognosis of CRC have been done using
univariate analysis that look for the value and influence
of each singular gene. The results presented provided
multiple parameters to allow a proper statistical assess-
ment and ranking of each gene survival markers
proposed (Table 3). To provide extra support to these
results we did another external validation using a second
independent cohort of CRC samples from the platform
SurvExpress [15]. The CRC dataset selected was called
“Colon-Metabase-Uniformized” and it included 482
samples with overall survival data and genome-wide ex-
pression determined with Affymetrix microarrays. We
performed several multivariate survival analyses (OS,
overall survival) on this dataset using combinations of
the top genes proposed in Table 3. As an example of
these analyses we present the KM plot (Additional file 5:
Figure S1) corresponding to the multivariate survival
study done using the top 5 genes found up-regulated for
poor survival (DCBLD2, PTPN14, LAMP5, TM4SF1 and
NPR3). It can be seen that the combination of these genes
provides a very good separation of two CRC populations:
one group of high-risk, associated to the overexpression (or
up-regulation) of the genes; and another group of low-risk,
associated to the lower expression (or down-regulation) of
these genes (Additional file 5: Figure S1). This analysis was
repeated with several other combinations of the top
up-regulated genes associated with poor survival (present
in Table 3), resulting in similar results. For example, com-
bining DCBLD2, LAMP5, TM4SF1, NPR3 and GADD45B
the separation of the high and low-risk groups improved a
bit: KM p-value = 2.21e-07 and HR = 2.23 (95% confidence
interval, CI: 1.65–3.02). Another combination that provided
very good separation was using genes DCBLD2, LAMP5,
TM4SF1, NPR3 and AKAP12: KM p-value = 2.51e-10 and
HR= 2.74 (95% CI: 2.00–3.74).
Gene expression profiles of CRC tumor samples versus
normal colorectal samples
All the integrated datasets, so far presented in this study
corresponded to CRC samples, because we want to
provide genes that are disease markers present in the
transformed tumor cells of the intestinal epithelium, and
genes that mark the progression and aggravation of this
type of cancer. In addition, we can only have survival in-
formation about patients since in healthy individuals sur-
vival time cannot be related to disease and there are not
disease-associated events. Despite this obvious consider-
ation, it is interesting to explore what would be the level of
expression of the genes, that we identified as survival
markers, when they are analysed in normal colorectal
tissue. Exploring back on the experimental series used to
create our meta-dataset of 1273 CRC samples, we found in
series GSE33113 and GSE39582 a collection of 25 samples
that corresponded to normal colorectal tissue. We took
these samples and included then with our CRC dataset
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1 ENSG00000057019 DCBLD2 0.0000000000 2.02 99 2.106 24627 discoidin; CUB and LCCL domain
containing 2 [HGNC:24627]
2 ENSG00000152104 PTPN14 0.0000000000 1.99 99 2.082 9647 protein tyrosine phosphatase;
non-receptor type 14
3 ENSG00000125869 LAMP5 0.0000000000 1.99 93 2.046 16097 lysosomal associated membrane
prot.member 5 [HGNC:16097]
4 ENSG00000169908 TM4SF1 0.0000000001 1.96 93 2.031 11853 transmembrane 4 L six family
member 1 [HGNC:11853]
5 ENSG00000113389 NPR3 0.0000000002 1.95 97 2.136 7945 natriuretic peptide receptor 3
[HGNC:7945]
6 ENSG00000186007 LEMD1 0.0000000003 1.95 85 1.937 18,725 LEM domain containing 1
[HGNC:18725]
7 ENSG00000135338 LCA5 0.0000000003 1.89 97 2.021 31,923 LCA5; lebercilin [HGNC:31923]
8 ENSG00000169826 CSGALNACT2 0.0000000008 1.91 92 1.974 24,292 chondroitin sulfate
N-acetylgalactosaminyltransferase 2
9 ENSG00000059804 SLC2A3 0.0000000014 1.93 89 1.993 11,007 solute carrier family 2 member 3
[HGNC:11007]
10 ENSG00000099860 GADD45B 0.0000000018 1.92 97 2.074 4096 growth arrest and DNA damage
inducible beta [HGNC:4096]
11 ENSG00000136155 SCEL 0.0000000018 1.88 87 1.928 10,573 sciellin [HGNC:10573]
12 ENSG00000100625 SIX4 0.0000000019 1.89 91 1.951 10,890 SIX homeobox 4 [HGNC:10890]
13 ENSG00000131016 AKAP12 0.0000000028 1.85 95 2.092 370 A-kinase anchoring protein 12
[HGNC:370]
14 ENSG00000158270 COLEC12 0.0000000028 1.84 92 1.941 16,016 collectin subfamily member 12
[HGNC:16016]
15 ENSG00000154553 PDLIM3 0.0000000047 1.84 91 1.985 20,767 PDZ and LIM domain 3
[HGNC:20767]
16 ENSG00000082781 ITGB5 0.0000000049 1.82 88 1.911 6160 integrin subunit beta 5
[HGNC:6160]
17 ENSG00000144366 GULP1 0.0000000050 1.81 88 1.911 18,649 engulfment adaptor PTB domain
containing 1 [HGNC:18649]
18 ENSG00000171951 SCG2 0.0000000051 1.81 93 2.034 10,575 secretogranin II [HGNC:10575]
19 ENSG00000185567 AHNAK2 0.0000000066 1.80 87 1.896 20,125 AHNAK nucleoprotein 2
[HGNC:20125]
20 ENSG00000138061 CYP1B1 0.0000000075 1.84 85 1.884 2597 cytochrome P450 family 1
subfamily B member 1
[HGNC:2597]
21 ENSG00000184304 PRKD1 0.0000000451 1.74 87 1.872 9407 protein kinase D1 [HGNC:9407]
22 ENSG00000152583 SPARCL1 0.0000000471 1.74 85 1.863 11,220 SPARC like 1 [HGNC:11220]
23 ENSG00000147883 CDKN2B 0.0000000717 1.73 84 1.847 1788 cyclin dependent kinase inhibitor
2B [HGNC:1788]
24 ENSG00000213190 MLLT11 0.0000001989 1.70 84 1.813 16,997 myeloid/lymphoid or mixed-lineage
leukemia; translocated to 11
25 ENSG00000135218 CD36 0.0000002751 1.69 85 1.891 1663 CD36 molecule [HGNC:1663]
1 ENSG00000133216 EPHB2 0.0000000000 0.43 100 0.426 3393 EPH receptor B2 [HGNC:3393]
2 ENSG00000169718 DUS1L 0.0000000000 0.49 98 0.481 30,086 dihydrouridine synthase 1 like
[HGNC:30086]
3 ENSG00000163545 NUAK2 0.0000000001 0.51 96 0.495 29,558 NUAK family kinase 2 [HGNC:29558]
4 ENSG00000158169 FANCC 0.0000000002 0.51 95 0.498 3584 Fanconi anemia complementation
group C [HGNC:3584]
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using the same normalization protocol. After this integra-
tion, we could explore the expression level of the top
up-regulated genes (identified as markers of poor survival),
comparing the expression distribution on a set of cancer
samples versus a set of normal tissue samples. In both cases
the number of samples compared were 25, since this is the
number of normal samples that we had. We did this com-
parison 20 times, random selecting each time a different
subset of 25 cancer samples. The results were always very
similar and the boxplots of the expression distributions for
the top 10 genes are presented in Additional file 6: Figure
S2. These results indicate that the gene markers, identified
in our survival studies, are most of the times also
up-regulated in CRC tumors with respect to normal colo-
rectal tissue.
Risk predictor score based in the multivariate analysis of
candidate survival markers
Finally, to obtain a more accurate evaluation of the prog-
nostic value of all the genes selected as best candidates
















5 ENSG00000277972 CISD3 0.0000000002 0.51 87 0.511 27,578 CDGSH iron sulfur domain 3
[HGNC:27578]
6 ENSG00000099800 TIMM13 0.0000000003 0.53 95 0.511 11,816 translocase of inner mitochondrial
membrane 13 [HGNC:11816]
7 ENSG00000116771 AGMAT 0.0000000005 0.52 95 0.515 18,407 agmatinase [HGNC:18407]
8 ENSG00000118513 MYB 0.0000000006 0.52 93 0.508 7545 MYB proto-oncogene. Transcription
factor [HGNC:7545]
9 ENSG00000016391 CHDH 0.0000000006 0.53 90 0.520 24,288 choline dehydrogenase
[HGNC:24288]
10 ENSG00000137460 FHDC1 0.0000000008 0.52 96 0.505 29,363 FH2 domain containing 1
[HGNC:29363]
11 ENSG00000132846 ZBED3 0.0000000009 0.52 88 0.522 20,711 zinc finger BED-type containing
3 [HGNC:20711]
12 ENSG00000162408 NOL9 0.0000000015 0.54 92 0.527 26,265 nucleolar protein 9 [HGNC:26265]
13 ENSG00000109534 GAR1 0.0000000017 0.50 99 0.479 14,264 GAR1 ribonucleoprotein
[HGNC:14264]
14 ENSG00000133477 FAM83F 0.0000000019 0.54 93 0.518 25,148 family with sequence similarity
83 member F [HGNC:25148]
15 ENSG00000100348 TXN2 0.0000000036 0.53 88 0.527 17,772 thioredoxin 2 [HGNC:17772]
16 ENSG00000108479 GALK1 0.0000000036 0.55 88 0.525 4118 galactokinase 1 [HGNC:4118]
17 ENSG00000110917 MLEC 0.0000000045 0.55 96 0.476 28,973 malectin [HGNC:28973]
18 ENSG00000114738 MAPKAPK3 0.0000000048 0.55 92 0.520 6888 mitogen-activated protein
kinase-activated 3 [HGNC:6888]
19 ENSG00000137752 CASP1 0.0000000180 0.56 87 0.523 1499 caspase 1 [HGNC:1499]
20 ENSG00000131844 MCCC2 0.0000000183 0.57 93 0.516 6937 methylcrotonoyl-CoA carboxylase
2 [HGNC:6937]
21 ENSG00000178409 BEND3 0.0000000193 0.55 88 0.529 23,040 BEN domain containing 3
[HGNC:23040]
22 ENSG00000114737 CISH 0.0000000216 0.55 87 0.508 1984 cytokine inducible SH2 containing
protein [HGNC:1984]
23 ENSG00000011376 LARS2 0.0000000239 0.55 91 0.528 17,095 leucyl-tRNA synthetase 2;
mitochondrial [HGNC:17095]
24 ENSG00000164045 CDC25A 0.0000000481 0.57 90 0.539 1725 cell division cycle 25A
[HGNC:1725]
25 ENSG00000154655 L3MBTL4 0.0000000606 0.54 90 0.506 26,677 l(3)mbt-like 4 (Drosophila)
[HGNC:26677]
The first part of the table corresponds to the top-25 genes where up-regulation corresponds to shorter survival and higher risk (i.e., HR > 1); the second part of the
table corresponds to the top-25 genes where UP-regulation corresponds to longer survival and lower risk (HR < 1). The genes were ranked by their KM adjusted p
values and the Hazard Ratio values calculated for the whole dataset, i.e. for all the 1273 samples (all-dt). The stability and robustness of the gene survival markers
was assessed by cross-validation, applying to each gene a resampling strategy with random selection of 80% of the samples 100 times (i.e. doing 100 iterations).
For the ranking we also considered that the genes had to give a significant adjusted p-value in more than 80 iterations (N-sinf-in-100i > 80)
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(reported in Additional files 2 and 3, Table S2 and
Table S3), we performed another analysis of the can-
didate markers using a regularized multivariate Cox
proportional-hazards regression with L1 norm penalty
[16], with the scope of building a multigenic “risk
predictor”. This analysis was done on the cohort of
1273 samples of CRC patients, using for the multi-
variate analysis the top 100 genes that showed
up-regulation correlated with poor prognosis (i.e.
overexpressed in low survival cases). The results are
presented in Fig. 4 that shows a graph ordering the
patients according to their risk score, from low-risk
(blue) to high-risk (red), including also an intermedi-
ate region (grey) (Fig. 4a). A recursive algorithm
using 10-fold cross-validation was applied to find the
value of risk score. The threshold (marked with a ver-
tical black line) is obtained by maximizing the separ-
ability between the survival curves for the resulting
groups. Therefore, it allows the best splitting of the
cohort in two groups. A Kaplan-Meier plot showing
the separation of these two groups is also presented
(Fig. 4b); dividing the population into a high risk
group including 425 individuals and a low risk group
including 848 individuals. As shown, the division is
significant (p-value = 8.25e-14) and allows an optimal
separation of individuals according to their survival.
The analysis of the beta factors assigned by the re-
gression to each of the top 100 genes, i.e. to each
variable within the multivariate vector (data included
in Additional file 7: Table S5), allows the identifi-
cation of the genes that were the most influential fac-
tors in this risk analysis and therefore it facilitated
the selection of the best “gene survival markers”. As
indicated in previous sections, the top 100 genes
included in the construction of this multigenic risk
predictor score were selected from the list of best
markers found during the survival test with single
genes.
Discussion
CRC is a complex disease composed of biologically and
clinically diverse subtypes, which can originate in differ-
ent ways provoking multiple clinical scenarios [1, 2].
This complexity causes the molecular characterization of
CRC to remain deficient, with a lack of clear gene markers
associated to specific CRC subtypes and to the prognosis
of the disease [17–19]. In fact, current molecular pheno-
typing of colorectal tumors is usually linked to the
Fig. 4 Risk prediction done for the cohort of 1273 patients of CRC based in the multivariate analysis using the top 100 genes that showed up-
regulation correlated with poor prognosis (i.e. overexpressed in low survival cases). a Plot presenting the patients according to their risk score,
from Low (blue) to High (red) risk. A recursive algorithm using 10-fold cross-validation finds the value of risk score (marked with a vertical black
line) that allows the best splitting of the cohort in two groups. b Kaplan-Meier plot showing the separation of these two groups: a high-risk
group including 425 individuals (in red) and a low-risk group including 848 individuals (in blue). The analysis has been done using a multivariate
Cox proportional-hazards regression. As shown, the division is very significant (p-value = 8.25e-14) and allows an optimal separation of individuals
according to their survival. The analysis of the beta factors assigned by the regression to each of the top 100 genes (i.e. to each variable within
the multivariate vector) allows the identification of the genes that are the most influential factors in this risk analysis and therefore it helps in the
selection of the best “gene survival markers”
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traditional determination of somatic mutations in well-
known oncogenes such as KRAS and BRAF [20].
The recent advance of genomic and transcriptomic
technologies applied to the study of clinical samples did
open the way to obtain genome-wide expression profiles
of multiple patient cohorts and correlate the expression
of certain genes with different disease subtypes, disease
stages and progression [21, 22]. This approach had been
widely applied in cancer research in the last decade and
is very powerful when the identification of marker genes
is associated with survival time. The correlation between
gene expression and survival is an excellent tool to
investigate prognosis of the disease and to build risk pre-
dictors that will be applicable to individual patients.
The identification of molecular biomarkers with prog-
nostic value in CRC has been a challenging task [23–26].
Molecular prognosis of colorectal tumor samples by
transcriptional profiling started about 15 years ago (see
review [24]), and in more recent years several specific
gene signatures associated with CRC survival have been
published [5–7, 27–31]. Despite these efforts, at present
there is not a clear compendium of gene markers for
CRC survival and it is quite difficult to find consistency
in the literature [24]. A clear limitation comes from the
fact that, in most of previous studies, the number of
tumor samples used to select the genes that enter into
the construction of the prognostic predictors is small
(i.e., the size of the patient cohorts rarely it is greater
than a few hundred individuals). For example, ColoPrint
is a 18-gene signature for prognosis prediction of stage
II and III CRC, that was identified using as training set
tumor samples from 188 patients [7, 27]; a 113-gene ex-
pression signature for predicting prognosis in patients
with CRC was built using 145 samples as dicovery set
[28]; a 7-gene signature to predict overall survival of
CRC patients was based in an initial training set of 67
samples [29]; a recurrence-associated CRC signature of
13 genes was developed using a screening set of 145
samples [30]; a 15-gene signature for prediction of CRC
recurrence and prognosis was elaborated using for the
gene selection a set of 55 patients [31]. In conclusion,
we can say that as far as it is reflected in the current litera-
ture, the size of the initial training sets used to identify
candidate gene markers for CRC survival is small and the
overlap between the published gene signatures is very re-
duced and inconsistent. To address these critical prob-
lems, we constructed a large, well-standardized, integrated
data set of 1273 tumor samples with survival information,
which was used to identify genes that had a clear change
in expression in the middle and late stages of CRC and
were consistent markers of the disease-outcome and
patient-risk.
With respect to the specific genes proposed as CRC
survival markers, we want to underline that our study
does not pretend to provide a fixed gene signature for
prognosis and risk prediction, like the reported signa-
tures of 7-genes, 15-genes or 113-genes [28, 29, 31]; but
instead we propose a robust set of genes ranked accor-
ding to their predictive power of CRC survival. In this
way, an ordered list of 200 genes including the best
survival markers is presented: 100 genes for which
up-regulation marks “poor survival” and 100 genes for
which up-regulation marks “good survival”. We think
that this approach is more useful, since it allows an open
selection of different number of genes for further
purposes or investigations (for example, for additional
tests with other CRC clinical cohorts). In fact, we used
the 100 most significant genes, up-regulated with the
progression of CRC, to build the risk predictor (pre-
sented in Fig. 4); and we used the top 5 or top 10 genes
of this list for the external validations with different
independent datasets.
Another relevant comment is that, as reminded above,
we constructed the risk predictor using the genes that
showed up-regulation correlated with poor prognosis.
This was done because in the selection of biomarkers it
is better to use the ones that provide a positive signal
(i.e. “gain-of-function” factors) than the ones that pro-
vide a negative signal. Therefore, all the gene survival
markers that we proposed were detectable as overex-
pressed in the CRC patients with high risk. The fact that
they give a positive signal will also make easier their
detection by standard biomolecular protocols (PCR,
ELISA, immunohistochemistry, etc).
Finally, we are investigating the biological meaning of
the genes found as best predictive and prognostic
markers. We are focusing our efforts in the top 10 for
which up-regulation marked poor survival: DCBLD2,
PTPN14, LAMP5, TM4SF1, NPR3, LEMD1, LCA5,
CSGALNACT2, SLC2A3, GADD45B. The analysis of
the literature reveals some relevant observations. For ex-
ample, the transmembrane protein DCBLD2 (ESDN),
member of a family of neuropilin-like proteins, is a novel
regulator of mitotic and metabolic effects of insulin, and
it modulates signal transduction through regulation of
the insulin receptor interaction with its adaptor proteins
[32]. The importance of insulin regulation in the func-
tion of our digestive system is clear, and this adds extra
value to the proposal of DCBLD2 as a CRC survival
marker. Other genes within the top rank have been
recently involved in cancer progression, like the case of
SLC2A3 (GLUT3) a glucose transporter that mediates
glucose utilization and glycogenolysis, which is induced
during epithelial-mesenchymal transition and promotes
tumor cell proliferation [33]. Recent publications have
also proposed the role of some other genes found as
prognostic markers, like the case of LAMP5 that has
been included in a multigenic assay to predict
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recurrence for gastric cancer patients after surgery [34].
As a final example, GADD45B (growth arrest and
DNA-damage-inducible 45 beta) is a gene that responds
to environmental stresses, associated with cell growth
control, apoptosis and DNA damage repair response.
GADD45B overexpression has been recently correlated
with shorter overall survival in colorectal carcinoma
[35]. Moreover, a recent integrative analysis of multiple
colon cancer gene-expression-based subtype classifiers
reported that one of the three highest scoring genes in-
cluded in several classifiers was GADD45B [36].
Despite all these positive findings that correspond to the
biological value and the support of the genes identified as
most significant markers of CRC survival, there are some
possible limitations of the results, beginning with the
general observation about the frequent heterogeneity of the
colorectal tumors [1, 17]. In fact, it is clear from the anatom-
ical pathology that CRC can affect quite different regions of
the digestive tract: ascending colon, transverse colon, de-
scending colon, sigmoid colon and rectum. The causal genes
that drive tumors in these different regions may not be the
same, and most CRC studies do not enter into a detailed
separation of these regions [19]. The variability due to the
different staging of the tumors is another factor that can
bring limitations to any CRC study; but in this case we
clearly indicated that our work searched for genes that were
candidate prognostic markers for CRC in stages III and IV.
A final reason for the limitations of the results may be an
over-adjustment to the tested data sets. To avoid this kind
of limitations, we built a large well-normalized data set with
more than a thousand samples, performed a cross-validation
analysis on that set, and also explored the validity of the
gene markers in two other independent sets.
Conclusions
In conclusion, we consider that the results presented in this
work provide strong support and a solid rationale for the
prognostic value of a new set of genes in CRC and for their
potential to predict colorectal tumor progression and evo-
lution towards stages III and IV. The final proposed set of
gene survival markers includes an open list of one hundred
up-regulated genes, with a robust statistical estimation of
the value of each one. In this way the set of genes is clearly
ranked, being the top in the list the ones that provide best
prognostic strength and the ones that can be introduced to
build smaller predictors. In fact, our results showed that a
selection of the top 5 genes applied to independent external
cohorts provided very good separation of CRC samples in
two distinct groups of high and low risk.
Methods
Genome-wide expression data sets
In this study, we have analysed and integrated seven data
sets of CRC samples (Table 1). All data sets are available
at GEO repository, corresponding to 7 series with the
following accession numbers: GSE14333, GSE17536,
GSE31595, GSE33113, GSE38832, GSE39084 and GSE
39582. All these series included the raw expression sig-
nal and correspond to data obtained with the microar-
rays expression platform: Affymetrix GeneChip U133
Plus 2.0 for Homo sapiens. The phenotypic information
corresponding to all these series was analysed in order
to select only the samples that included information re-
garding: the cancer stage and the Overall Survival (OS).
The samples that did not have any survival information
were discarded from the study. In all cases only primary
tumors samples were considered for our analysis; in this
way individuals who had received preoperative chemo-
therapy and/or radiotherapy were also discarded.
For the external validation we used two independent
datasets. A cohort of 276 colorectal carcinomas that had
been studied using RNA-seq gene expression profiling,
and that had survival data for 269 samples [14] (which
can be found in http://tcga-data.nci.nih.gov/docs/publi-
cations/coadread_2012/). A second cohort of CRC sam-
ples from the platform SurvExpress [15]. This second
dataset selected, called “Colon-Metabase-Uniformized”,
included 482 CRC samples with overall survival data
and genome-wide expression determined with Affyme-
trix microarrays (see the website http://bioinformati-
ca.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp).
Expression data sets exploration and integrative
normalization
Previously, to make the best use of the information
obtained from the microarrays, we have considered the
importance to ascertain the quality of the data. To assess
the validity of generated microarray information we have
performed a wide variety of quality assessment methods,
both in raw and pre-processed information. In this way,
several explanatory data analysis were applied for the de-
tection of problematic arrays. We used the R function
image to create chip images of the raw intensities to dis-
cover spatial artefacts in the samples. We have also look
at the distribution of probes intensities across all arrays,
using the boxplot method available for the Affybatch
class. We also applied to the samples the Normalized
Unscaled Standard Error (NUSE) algorithm. This quality
assessment tool requires a previous PLM fitting proced-
ure applied on the raw expression data. We have used
the function fitPLM provided in the AffyPLM package to
create the PLMset class object used as the input in the
elaboration of the NUSE analysis. After applying the re-
ferred quality assessment methods, we discarded 79 of
the initial samples collected and proceed with the
remaining 1273 (Table 1).
To create a table with all the phenotypic characteris-
tics of the patients selected which involved all samples
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GSM accession numbers and related clinic variables in a
consistent and homogenize way, we used getGEO and
pData functions from GEOquery package (this table is
provided as Additional file 1: Table S1). We made use of
regular expressions and common text manipulation R
functions to solve the issue of formatting heterogenic
data. Finally, we created a binary variable to label the
patients and select them in a proper way during the
hypothesis contrasts and statistical modeling.
Batch effect removal
Batch effect is one of the main problems when several
datasets are combined to be studied together, because
different batches usually add large unwanted variability to
the data. To avoid this effect we tested a combination of
different pre-processing and normalization algorithms:
Robust Multi-array Average (RMA) algorithm [11];
Combatting Batch effects (ComBat) algorithm [12]; Fro-
zen Robust Multi-array Average (fRMA) algorithm [13].
For the fRMA algorithm application, we constructed the
frozen parameter vector using a training dataset in where
we distributed randomly selected samples proportionally
to each labelled group to obtain a balanced sample from
the 7 batches of microarrays.
Another important issue addressed was the fact that
the Affymetrix probe-sets included in the expression
microarrays many times do not correspond to singular
genes and some probes inserted in the defined
probe-sets are ambiguous or inaccurate [10]. Affymetrix
GeneChip is a popular and usefull platform for gene ex-
pression profiling, but the use of its probes and
probe-sets mapping has multiple inconveniences. In fact,
the probe-sets for the Affymetrix Human Genome U133
Plus 2.0 Array are based on UniGene database (Build 133,
April 20, 2001) and considering how rapidly human genome
has evolved many probes on the array are not correctly
assigned. To avoid this problem, we used the updated probe
alignment and gene mapping that is provided by the Chip
Definition File (CDF): hgu133plus2hsensgcdf (downloaded
from http://brainarray.mbni.med.umich.edu/).
Batch effect removal evaluation
We performed unsupervised hierarchical clustering to
observe unlikely clustering based on batches in those ex-
pression value matrixes where batch effects remained
after pre-processing. We used a 30-random sampling
per batch, identifying each batch by a different color
(Fig. 1). The batch effect was also investigated using
principal components analysis (PCA) (Fig. 2). A linear
regression of average gene expression on array batch per
pre-processing method was the final approach fulfilled
to assure removal (Table 2).
Differential expression analysis
For the identification of gene whose altered expression
achieved statistical significance we used the R algorithm
Linear Models for Microarrays (LIMMA package). We
applied LIMMA to the expression data matrix fixing an
adjusted p-value threshold of FDR ≤ 0.01 to select sig-
nificant genes. The comparison was done separating the
samples according to their clinical and pathological stage
(comparing CRC stages I and II versus III and IV). In
this way we found a set of 2707 candidates genes, corre-
sponding to 2524 protein-coding genes that were tested
in the survival analysis (the rest were non-coding genes).
In this work we focus only on the genes that encode
proteins because we wanted to find CRC survival
markers that later can be tested at protein level using,
for example, immunohistochemistry (IHC) analysis.
Survival analysis
Our intention in this research was to identify genes whose
relative expression level affect survival and prognosis in
CRC, once we had made a preselection in its behavior
through stage evolution of 2524 protein-coding genes.
The first step for the survival analysis was to define for
each gene two separated distributions of high and low
expression along the sample dataset investigated. This separ-
ation based in expression level determined the explanatory
variable. We used the Surdiff function in the Survival pack-
age to address the issue. By sorting all the samples in ascend-
ing order, we performed Surdiff hypothesis testing, splitting
the group of samples for each gene and every sample be-
tween quantile 25% and 75% to obtain its Chi-square associ-
ated p-value. Then we selected minimum p-value to perform
final group assignation of high and low expression. Once we
had the two groups clearly defined, we used the Coxph
model to obtain each associated p-value and hazard ratio
(HR) from every candidate gene. In this way, the survival
analysis along the two groups also allowed estimating hazard
ratios (HR) or, what is the same, tried to measure how the
expression, in terms of high and low relative expression for
each candidate gene, altered the hazard function. Finally, for
computing the time to event, the response variable in the
models was the Overall Survival (OS) time. All the data sets
that we integrated in our analyses had OS information. In
some cases for some individuals, Disease Specific Survival
(DSS) times or Relapse Free Survival (RFS) times were also
provided with the original data, but we did not considered
these time-events since we wanted to focus on OS to achieve
a homogeneous analysis.
Additional files
Additional file 1: Table S1. Phenotypic and clinical information about
the collection of 1273 colorectal cancer samples that has been integrated
in this work. The table includes the IDs of the samples in GEO and all the
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available data about age, gender, survival time, location of the tumor,
degree and TNM staging, presence of mutation in some cancer genes
(TP53, KRAS, BRAF), etc. When information was not available for a given
sample the table includes NA (not available values). (XLSX 272 kb)
Additional file 2: Table S2. Top-100 best survival marker genes for
colorectal cancer (CRC) that are up-regulated when survival is poor and
the risk is higher (i.e., HR > 1). This table is an expension of the data in
Table 3. The genes were ranked by their KM adjusted p-values and the
HR values calculated for the whole dataset (i.e. for all the 1273 samples
= all-dt). The stability of each survival marker gene was assessed by
cross-validation (100 iterations). The table also includes the number of
times that a survival marker was significant in the iterations (N-sinf-in-
100i). (XLSX 73 kb)
Additional file 3: Table S3. Top-100 best survival marker genes for
colorectal cancer (CRC) that are down-regulated when survival is poor
and the risk is higher (i.e., HR < 1). This table is an expension of the data
in Table 3. The genes were ranked by their KM adjusted p-values and the
HR values calculated for the whole dataset (i.e. 1273 samples = all-dt).
The stability of each survival marker gene was assessed by cross-
validation (100 iterations). The table also includes the number of times
that a survival marker was significant in the iterations (N-sinf-in-100i).
(XLSX 70 kb)
Additional file 4: Table S4. Validation of the survival data done in an
independent set of samples taken from The Cancer Genome Atlas
(TCGA), that included 269 colorectal carcinomas with survival information
and RNA-seq global expression profiling. The table includes the KM p-
values and HR of the genes that were validated from the top-10 survival
marker genes previously found presented in Table 3. Of the top-10 for
the case of up-regulation associated with poor survival, 7 were validated
(PTPN14, LAMP5, TM4SF1, LCA5, CSGALNACT2, SLC2A3 and GADD45B). Of
the top-10 found for down-regulation associated with poor survival, 6
genes were validated (EPHB2, DUS1L, NUAK2, FANCC, MYB and CHDH).
(XLSX 51 kb)
Additional file 5: Figure S1. Survival multivariate analysis of an
independent set of 482 samples of CRC patients carried out considering
the expression profiles of 5 genes: DCBLD2, PTPN14, LAMP5, TM4SF1 and
NPR3. (A) Kaplan-Meier plot presenting the patients divided in two
groups according their risk score: High risk (red) and Low risk (green). (B)
Box plots showing the distributions of global expression corresponding
to these 5 genes. For each gene, the dataset of 482 samples was divided
in the two groups of patients indentified as High risk (red) and Low risk
(green). (PDF 356 kb)
Additional file 6: Figure S2. Comparison of the distributions of the
expression signal corresponding to ten genes in 25 samples from normal
colorectal epithelium (green boxplots) versus 25 samples from CRC (red
boxplots). The genes selected for this analysis were the top-10 best sur-
vival marker genes found up-regulated for poor prognosis (i.e. markers
up-regulated when there is low CRC survival): DCBLD2, PTPN14, LAMP5,
TM4SF1, NPR3, LEMD1, LCA5, CSGALNACT2, SLC2A3 and GADD45B. The
tumor samples were not selected by stage (i.e. they were selected from
any CRC stage: I, II, III or IV) and this comparison was done 20 times with
different subsets of 25 CRC samples to check the stability of the signal.
The plots of all the other comparisons were very similar to the plot here
presented. (PDF 46 kb)
Additional file 7: Table S5. Beta factors assigned by regression analysis
to each of the top-100 survival marker genes. These genes are taken as
variables within the multivariate Kaplan-Meier survival analysis included in
Fig. 4b. The factors allowed the identification of the genes that were the
most influential variables in this risk analysis (i.e. the higher the better)
and therefore facilitate an additional evaluation of each survival marker
gene. (XLSX 62 kb)
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